Mondor's disease following the third dose of BNT162b2 m-RNA COVID-19 vaccine

International Journal of DermatologyVolume 63, Issue 1 p. 111-112 Clinical correspondence Mondor's disease following the third dose of BNT162b2 m-RNA COVID-19 vaccine Francesco Drago MD, Francesco Drago MD Department of Health Sciences, Section of Dermatology, DISSAL, University of Genoa, Ospedale-Policlinico San Martino, IRCCS, Genova, ItalySearch for more papers by this authorGiuseppe Cittadini MD, Giuseppe Cittadini MD General Radiology, Polyclinic San Martino Hospital, IRCCS for Oncology and Neuroscience, Genoa, ItalySearch for more papers by this authorAlessandro Garlaschi MD, Alessandro Garlaschi MD General Radiology, Polyclinic San Martino Hospital, IRCCS for Oncology and Neuroscience, Genoa, ItalySearch for more papers by this authorGiulia Ciccarese MD, PhD, Corresponding Author Giulia Ciccarese MD, PhD [email protected] Department of Medical and Surgical Sciences, Unit of Dermatology, University of Foggia, Foggia, ItalySearch for more papers by this author Francesco Drago MD, Francesco Drago MD Department of Health Sciences, Section of Dermatology, DISSAL, University of Genoa, Ospedale-Policlinico San Martino, IRCCS, Genova, ItalySearch for more papers by this authorGiuseppe Cittadini MD, Giuseppe Cittadini MD General Radiology, Polyclinic San Martino Hospital, IRCCS for Oncology and Neuroscience, Genoa, ItalySearch for more papers by this authorAlessandro Garlaschi MD, Alessandro Garlaschi MD General Radiology, Polyclinic San Martino Hospital, IRCCS for Oncology and Neuroscience, Genoa, ItalySearch for more papers by this authorGiulia Ciccarese MD, PhD, Corresponding Author Giulia Ciccarese MD, PhD [email protected] Department of Medical and Surgical Sciences, Unit of Dermatology, University of Foggia, Foggia, ItalySearch for more papers by this author First published: 13 November 2023 https://doi.org/10.1111/ijd.16910 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Stoneham S, Hughes B, Agrawal A. A memorable patient- a case of mondor's disease following axillary sentinel lymph node biopsy. Clin Exp Dermatol. 2023; 48(8): 956–958. https://doi.org/10.1093/ced/llad132 10.1093/ced/llad132 PubMedWeb of Science®Google Scholar 2Amano M, Shimizu T. Mondor's disease: a review of the literature. Intern Med. 2018; 57: 2607–2612. 10.2169/internalmedicine.0495-17 PubMedWeb of Science®Google Scholar 3Levi I, Baum M. Mondor's disease as a presenting symptom of breast cancer. Br J Surg. 1987; 74: 700. 10.1002/bjs.1800740817 CASPubMedWeb of Science®Google Scholar 4Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med. 2021; 16: 803–804. 10.1007/s11739-021-02685-0 PubMedWeb of Science®Google Scholar 5Drago F, Broccolo F, Ciccarese G. Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination. Clin Dermatol. 2022; 40: 586–590. 10.1016/j.clindermatol.2022.01.002 PubMedWeb of Science®Google Scholar 6Danish FI, Rabani AE, Subhani FE, Yasmin S, Koul SS. COVID-19: Vaccine-induced immune thrombotic thrombocytopenia. Eur J Haematol. 2022; 109(6): 619–632. https://doi.org/10.1111/ejh.13855 10.1111/ejh.13855 CASPubMedWeb of Science®Google Scholar Volume63, Issue1January 2024Pages 111-112 ReferencesRelatedInformation